Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Enhertu Could Get Big Boost From Second-Line Breast Cancer Indication

Executive Summary

An analyst forecast that about 40% of the drug’s sales could come from second-line disease, while lack of grade 4-5 interstitial lung disease events was seen as a plus.

You may also be interested in...



Daiichi Vows Action As $41.8m Patent Decision Favors Seagen

A US jury decision in a long-running ADC patent dispute between Seagen and Daiichi Sankyo has found in favor of the US firm. But Daiichi has vowed to challenge the outcome while its motion to question the validity of the original patent on which the case is based has also just been granted, meaning the final impact remains uncertain.

Enhertu Poised To Rewrite The Standard Of Care After ESMO

AstraZeneca/Daiichi Sankyo's Enhertu is poised to become the new standard of care for second-line HER2-positive breast cancer after handedly beating Roche's Kadcyla on PFS.

Lackluster Survival Data Likely To Marginalize MacroGenics’ Margenza

While the general lack of an overall survival benefit for MacroGenics’ drug in later-line breast cancer was not surprising, OS data were seen as important for commercial uptake of the drug.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC144871

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel